Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eitan Kerem

Showing results (1-10 of 175) with videos related to

Pageof 18
Sort By:
Pediatric Pulmonology|December 3, 2024
Expanding the Impact of New Cystic Fibrosis Therapies in Low- and Middle-Income CountriesEitan Kerem
Expert Opinion on Investigational Drugs|September 25, 2020
ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic diseaseEitan Kerem
Paediatric Respiratory Reviews|June 27, 2006
Mutation specific therapy in CFEitan Kerem
Current Opinion in Pulmonary Medicine|October 29, 2004
Pharmacologic therapy for stop mutations: how much CFTR activity is enough?Eitan Kerem
Paediatric Respiratory Reviews|July 13, 2017
Cystic fibrosis: Priorities and progress for future therapiesEitan Kerem
Paediatric Respiratory Reviews|June 27, 2006
Atypical CF and CF related diseasesEitan Kerem
Pediatric Pulmonology|May 10, 2005
Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapyEitan Kerem
Expert Opinion on Investigational Drugs|July 13, 2011
New drugs for cystic fibrosisMichael Wilschanski, Eitan Kerem
Pediatric Pulmonology|September 26, 2007
Early intervention in CF: how to monitor the effectGiora Weiser, Eitan Kerem
Chest|February 13, 2016
Disparities in Cystic Fibrosis Care and Outcome: Socioeconomic Status and BeyondEitan Kerem, Malena Cohen-Cymberknoh
Pageof 18

Showing results (1-10 of 175) with videos related to

Sort By:
Pageof 18
Pediatric Pulmonology|December 3, 2024
Expanding the Impact of New Cystic Fibrosis Therapies in Low- and Middle-Income CountriesEitan Kerem
Expert Opinion on Investigational Drugs|September 25, 2020
ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic diseaseEitan Kerem
Paediatric Respiratory Reviews|June 27, 2006
Mutation specific therapy in CFEitan Kerem
Current Opinion in Pulmonary Medicine|October 29, 2004
Pharmacologic therapy for stop mutations: how much CFTR activity is enough?Eitan Kerem
Paediatric Respiratory Reviews|July 13, 2017
Cystic fibrosis: Priorities and progress for future therapiesEitan Kerem
Paediatric Respiratory Reviews|June 27, 2006
Atypical CF and CF related diseasesEitan Kerem
Pediatric Pulmonology|May 10, 2005
Pharmacological induction of CFTR function in patients with cystic fibrosis: mutation-specific therapyEitan Kerem
Expert Opinion on Investigational Drugs|July 13, 2011
New drugs for cystic fibrosisMichael Wilschanski, Eitan Kerem
Pediatric Pulmonology|September 26, 2007
Early intervention in CF: how to monitor the effectGiora Weiser, Eitan Kerem
Chest|February 13, 2016
Disparities in Cystic Fibrosis Care and Outcome: Socioeconomic Status and BeyondEitan Kerem, Malena Cohen-Cymberknoh
Pageof 18